Advertisement
Advertisement
U.S. markets open in 1 hour 34 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Bonus BioGroup Ltd. (BONS.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
Add to watchlist
132.00-0.60 (-0.45%)
As of 2:38PM IDT. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close132.60
Open132.10
Bid132.00 x 100
Ask132.30 x 624100
Day's Range129.90 - 133.10
52 Week Range36.40 - 175.00
Volume1,580,588
Avg. Volume5,005,246
Market Cap152.251B
Beta (5Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BONS.TA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ACCESSWIRE

      Bonus BioGroup Reports Resounding Success in Phase-I Clinical Trials for Regenerative COVID-19 Treatment

      TEL AVIV, ISRAEL / ACCESSWIRE / July 19, 2021 / Bonus BioGroup LTD (TASE:BONS), an Israeli clinical-stage biotechnology company, announced further improvements in key parameters measured in phase I/II Clinical Trials for its advanced cell therapy product, MesenCure. The latest report follows Bonus BioGroup's May 27th announcement of MesenCure'scomplete success in the treatment of severe COVID-19 patients suffering from life-threatening pneumonia and acute respiratory distress.

    Advertisement
    Advertisement